Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Safronetz

Showing results (11-20 of 166) with videos related to

Pageof 17
Sort By:
Drug Design, Development and Therapy|August 28, 2018
Current research for a vaccine against Lassa hemorrhagic fever virusBryce M Warner, David Safronetz, Derek R Stein
Advances in Experimental Medicine and Biology|October 11, 2016
Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic MethodsBryce M Warner, David Safronetz, Gary P Kobinger
Plos Computational Biology|January 7, 2021
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirinGuillaume Lingas, Kyle Rosenke, David Safronetz, et al.
Virology Journal|December 20, 2024
Current perspectives on vaccines and therapeutics for Lassa FeverBryce M Warner, David Safronetz, Derek R Stein
Antiviral Research|June 19, 2012
The Syrian hamster model of hantavirus pulmonary syndromeDavid Safronetz, Hideki Ebihara, Heinz Feldmann, et al.
Emerging Infectious Diseases|February 21, 2025
Sin Nombre Virus as Unlikely Reverse Zoonotic ThreatJérémie Prévost, Nikesh Tailor, Anders Leung, et al.
Journal of Immunological Methods|February 22, 2011
Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)Marko Zivcec, David Safronetz, Elaine Haddock, et al.
Science (New York, N.Y.)|August 13, 2016
Response to Comment on "Mutation rate and genotype variation of Ebola virus from Mali case sequences"Thomas Hoenen, Allison Groseth, David Safronetz, et al.
Plos One|August 20, 2011
In vitro and in vivo activity of ribavirin against Andes virus infectionDavid Safronetz, Elaine Haddock, Friederike Feldmann, et al.
Plos Neglected Tropical Diseases|July 17, 2018
Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challengeMarko Zivcec, David Safronetz, Dana P Scott, et al.
Pageof 17

Showing results (11-20 of 166) with videos related to

Sort By:
Pageof 17
Drug Design, Development and Therapy|August 28, 2018
Current research for a vaccine against Lassa hemorrhagic fever virusBryce M Warner, David Safronetz, Derek R Stein
Advances in Experimental Medicine and Biology|October 11, 2016
Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic MethodsBryce M Warner, David Safronetz, Gary P Kobinger
Plos Computational Biology|January 7, 2021
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirinGuillaume Lingas, Kyle Rosenke, David Safronetz, et al.
Virology Journal|December 20, 2024
Current perspectives on vaccines and therapeutics for Lassa FeverBryce M Warner, David Safronetz, Derek R Stein
Antiviral Research|June 19, 2012
The Syrian hamster model of hantavirus pulmonary syndromeDavid Safronetz, Hideki Ebihara, Heinz Feldmann, et al.
Emerging Infectious Diseases|February 21, 2025
Sin Nombre Virus as Unlikely Reverse Zoonotic ThreatJérémie Prévost, Nikesh Tailor, Anders Leung, et al.
Journal of Immunological Methods|February 22, 2011
Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)Marko Zivcec, David Safronetz, Elaine Haddock, et al.
Science (New York, N.Y.)|August 13, 2016
Response to Comment on "Mutation rate and genotype variation of Ebola virus from Mali case sequences"Thomas Hoenen, Allison Groseth, David Safronetz, et al.
Plos One|August 20, 2011
In vitro and in vivo activity of ribavirin against Andes virus infectionDavid Safronetz, Elaine Haddock, Friederike Feldmann, et al.
Plos Neglected Tropical Diseases|July 17, 2018
Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challengeMarko Zivcec, David Safronetz, Dana P Scott, et al.
Pageof 17